Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Chemistry Outsourcing

Stephen Shuttleworth's Biography



Stephen Shuttleworth, CSO, Karus Therapeutics

Stephen joined Karus in January 2008 as Chief Scientific Officer. He has 17 years experience in small molecule drug discovery and R&D management gained in the UK and North American biotech industry, including at Celltech-Chiroscience, Shire Pharmaceuticals, Amgen, and Piramed where he was Director of Chemistry and PI3K Programme Leader. At Piramed, Stephen was responsible for the design and preclinical development of GDC-0941, which is currently in clinical trials for the treatment of cancer, and he played a central role in establishing a major R&D collaboration with Genentech in 2005. Prior to Karus, Stephen was Head of New Projects Development at CRUK in London, responsible for CRUK's New Agents Committee and for establishing the portfolio of Phase I and II clinical programmes.
Stephen obtained his BSc and PhD in Chemistry from the University of Liverpool. He has authored more than 90 publications and patents, and is a Fellow of the Royal Society of Chemistry.

Stephen Shuttleworth Image

Targeted Small Molecule Lead Discovery, Optimisation and Development in a Semi-Virtual R&D Environment

Tuesday, 13 March 2012 at 10:00

Add to Calendar ▼2012-03-13 10:00:002012-03-13 11:00:00Europe/LondonTargeted Small Molecule Lead Discovery, Optimisation and Development in a Semi-Virtual RandD EnvironmentSELECTBIOenquiries@selectbiosciences.com

Creating a unique scientific angle; building the right internal team of experimentalists; establishing a network of CROs with the requisite experimental capabilities in preclinical research, and in clinical development; case histories outlining the design of novel therapeutics for treating immune-inflammatory diseases and cancer.


Add to Calendar ▼2012-03-13 00:00:002012-03-14 00:00:00Europe/LondonChemistry OutsourcingSELECTBIOenquiries@selectbiosciences.com